Literature DB >> 15961076

Circulating fragmented nucleosomal DNA and caspase-3 mRNA in patients with lymphoma and myeloma.

Ugur Deligezer1, Nilgün Erten, Ebru E Akisik, Nejat Dalay.   

Abstract

Elevated amounts of cell-free nucleic acids are detected in the circulation of cancer patients. The type and pattern of these may vary depending on the origin. Recently, we described the presence of circulating fragmented nucleosomal DNA. In the present study, our aim was to investigate the association between nucleosomal DNA, caspase-3 expression and circulating caspase-3 mRNA, the primary activator of nucleosomal DNA fragmentation. DNA fragmentation was analyzed by gel electrophoresis, and caspase-3 was analyzed by RT-PCR. Plasma samples from 65% of patients were positive for nucleosomal DNA fragmentation, whereas none of the healthy controls showed DNA fragmentation (P = 0.0004). Expression of caspase-3 differed significantly between the cases and controls (P < 0.0001). However, we observed no direct correlation between nucleosomal DNA fragmentation and caspase-3 expression in lymphocytes (P = 0.145). Circulating plasma caspase-3 mRNA was detected by nested RT-PCR, and no significant difference was observed between the patients and the control group (P = 0.5). Our results indicate that caspase-3 expression is increased in lymphocytes from patients. When compared to healthy individuals, no differences were observed in the amount of circulating mRNA. These findings suggest that nucleosomal DNA fragmentation is not correlated with elevated levels of apoptosis and circulating caspase-3 mRNA in circulating tumor cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15961076     DOI: 10.1016/j.yexmp.2005.05.001

Source DB:  PubMed          Journal:  Exp Mol Pathol        ISSN: 0014-4800            Impact factor:   3.362


  17 in total

1.  Expression of the TRAIL receptors in blood mononuclear cells in leukemia.

Authors:  Ugur Deligezer; Nejat Dalay
Journal:  Pathol Oncol Res       Date:  2007-12-25       Impact factor: 3.201

2.  Issues on fit-for-purpose validation of a panel of ELISAs for application as biomarkers in clinical trials of anti-Angiogenic drugs.

Authors:  K Brookes; J Cummings; A Backen; A Greystoke; T Ward; G C Jayson; C Dive
Journal:  Br J Cancer       Date:  2010-04-20       Impact factor: 7.640

3.  Dielectrophoretic isolation and detection of cancer-related circulating cell-free DNA biomarkers from blood and plasma.

Authors:  Avery Sonnenberg; Jennifer Y Marciniak; Elaine A Skowronski; Sareh Manouchehri; Laura Rassenti; Emanuela M Ghia; George F Widhopf; Thomas J Kipps; Michael J Heller
Journal:  Electrophoresis       Date:  2014-05-14       Impact factor: 3.535

4.  Circulating Cell-Free DNA from Colorectal Cancer Patients May Reveal High KRAS or BRAF Mutation Load.

Authors:  Florent Mouliere; Safia El Messaoudi; Celine Gongora; Anne-Sophie Guedj; Bruno Robert; Maguy Del Rio; Franck Molina; Pierre-Jean Lamy; Evelyne Lopez-Crapez; Muriel Mathonnet; Marc Ychou; Denis Pezet; Alain R Thierry
Journal:  Transl Oncol       Date:  2013-06-01       Impact factor: 4.243

5.  Rapid electrokinetic isolation of cancer-related circulating cell-free DNA directly from blood.

Authors:  Avery Sonnenberg; Jennifer Y Marciniak; Laura Rassenti; Emanuela M Ghia; Elaine A Skowronski; Sareh Manouchehri; James McCanna; George F Widhopf; Thomas J Kipps; Michael J Heller
Journal:  Clin Chem       Date:  2013-11-22       Impact factor: 8.327

6.  Circulating nuclear DNA structural features, origins, and complete size profile revealed by fragmentomics.

Authors:  Cynthia Sanchez; Benoit Roch; Thibault Mazard; Philippe Blache; Zahra Al Amir Dache; Brice Pastor; Ekaterina Pisareva; Rita Tanos; Alain R Thierry
Journal:  JCI Insight       Date:  2021-04-08

7.  Apoptosis-related deregulation of proteolytic activities and high serum levels of circulating nucleosomes and DNA in blood correlate with breast cancer progression.

Authors:  Carina Roth; Klaus Pantel; Volkmar Müller; Brigitte Rack; Sabine Kasimir-Bauer; Wolfgang Janni; Heidi Schwarzenbach
Journal:  BMC Cancer       Date:  2011-01-06       Impact factor: 4.430

8.  Assessment of circulating biomarkers for potential pharmacodynamic utility in patients with lymphoma.

Authors:  A Greystoke; J P B O'Connor; K Linton; M B Taylor; J Cummings; T Ward; F Maders; A Hughes; M Ranson; T M Illidge; J Radford; C Dive
Journal:  Br J Cancer       Date:  2011-01-18       Impact factor: 7.640

9.  Fatal outcome in bacteremia is characterized by high plasma cell free DNA concentration and apoptotic DNA fragmentation: a prospective cohort study.

Authors:  Reetta Huttunen; Taru Kuparinen; Juulia Jylhävä; Janne Aittoniemi; Risto Vuento; Heini Huhtala; Janne Laine; Jaana Syrjänen; Mikko Hurme
Journal:  PLoS One       Date:  2011-07-01       Impact factor: 3.240

10.  Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts.

Authors:  Alain R Thierry; Florent Mouliere; Celine Gongora; Jeremy Ollier; Bruno Robert; Marc Ychou; Maguy Del Rio; Franck Molina
Journal:  Nucleic Acids Res       Date:  2010-05-21       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.